GIBSON DUNN

# Gibson Dunn Advises Avere Therapeutics on Reverse Merger with NextCure, and Concurrent Private Financing

Firm News | July 20, 2026

---

Gibson Dunn is advising Avere Therapeutics, Inc. on its reverse merger transaction with NextCure, Inc. (NASDAQ: NXTC) and concurrent $320 million private financing of shares of common stock and pre-funded warrants to a syndicate of healthcare investors. Upon completion of the transaction, the combined company plans to operate under the name Avere Therapeutics, Inc. and trade on Nasdaq under a new ticker symbol.

The Gibson Dunn corporate team is led by partners Ryan Murr and Branden Berns and includes of counsel Evan Shepherd.

### Related People

Ryan A. Murr

Branden C. Berns

Evan Shepherd

### Related Capabilities

Mergers and Acquisitions

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at <a href="https://www.gibsondunn.com">www.gibsondunn.com</a>. | **www.gibsondunn.com**